ADITEC is a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research partners collaborate in the ADITEC project.
ADITEC comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered.
ADITEC started in October 2011, is a 5-year project and has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No 280873. Recently the European Commission approved a one year no cost extension postponing the end of the project to 30 September 2017.
On November 8, 2016, ADITEC was presented as a Success Story at the European Parliament in the Working Breakfast on “Vaccine Research and Development in Europe”. Key opinion leaders including representatives from the European Commission, the European Parliament and leading experts in the field of vaccines R&D joined this high-level event